Efficacy of Mirabegron for Treatment of Non-monosymptomatic Nocturnal Enuresis in Children

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07398261

Enrollment

151

Registered

2026-02-09

Start date

2023-08-28

Completion date

2026-11-01

Last updated

2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Treatment of Non-monosymptomatic Nocturnal Enuresis

Brief summary

This phase 3 clinical trial will compare use of individual treatment with mirabegron or desmopressin and their combination for treatment of non-monosymptomatic nocturnal enuresis in children

Interventions

DRUGMirabegron 25 MG

Evaluate the efficacy of individual mirabegron or in combination for treatment of non-monosymptomatic nocturnal enuresis in children

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

\- Non-monosymptomatic nocturnal enuresis

Exclusion criteria

* monosymptomatic nocturnal enuresis

Design outcomes

Primary

Measure	Time frame
Partial or complete response	18 months

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026